| Active Not Recruiting | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Diffuse Large B-Cell Lymphoma | Phase 3 | 2020-10-08 |
| Terminated | Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19 COVID-19 | Phase 1 | 2020-09-21 |
| Completed | A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) Healthy Volunteers | Phase 1 | 2020-01-03 |
| Active Not Recruiting | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA10 Chronic Lymphocytic Leukemia | Phase 3 | 2019-02-25 |
| Completed | Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabo Hepatic Impairment, Hepatic Insufficiency, Healthy Subjects | Phase 1 | 2018-11-12 |
| Completed | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) NHL, DLBCL, Non-hodgkin's Lymphoma | Phase 1 | 2018-06-19 |
| Active Not Recruiting | A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL Chronic Lymphocytic Leukemia | Phase 1 | 2018-01-31 |
| Terminated | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies DLBCL, Richter Syndrome | Phase 1 / Phase 2 | 2017-06-29 |
| Active Not Recruiting | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL Lymphoma, Mantle Cell | Phase 3 | 2017-04-05 |
| Active Not Recruiting | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab Chronic Lymphocytic Leukemia | Phase 3 | 2017-02-02 |
| Completed | A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participa Healthy Volunteers | Phase 1 | 2016-06-03 |
| Withdrawn | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Mantle Cell Lymphoma | Phase 3 | 2016-05-01 |
| Active Not Recruiting | A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL Mantle Cell Lymphoma (MCL) | Phase 1 | 2016-04-20 |
| Completed | A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participant Healthy Volunteers | Phase 1 | 2016-04-01 |
| Active Not Recruiting | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therap Chronic Lymphocytic Leukemia | Phase 2 | 2016-03-08 |
| Completed | A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants Healthy Volunteers | Phase 1 | 2016-03-03 |
| Completed | A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapef Healthy Volunteers | Phase 1 | 2016-01-28 |
| Active Not Recruiting | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM Glioblastoma Multiforme | Phase 1 / Phase 2 | 2016-01-25 |
| Completed | Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) Ovarian Cancer | Phase 2 | 2015-11-01 |
| Terminated | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreat Metastatic Pancreatic Cancer | Phase 2 | 2015-10-13 |
| Active Not Recruiting | Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Ly Chronic Lymphocytic Leukemia | Phase 3 | 2015-07-28 |
| Active Not Recruiting | Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL Chronic Lymphocytic Leukemia | Phase 3 | 2015-06-26 |
| Completed | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer | Phase 2 | 2015-05-01 |
| Completed | Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Squamous Cell Carcinoma of the Head and Neck | Phase 2 | 2015-05-01 |
| Completed | Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell L Carcinoma, Non-Small-Cell Lung | Phase 2 | 2015-05-01 |
| Completed | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder C Metastatic Urothelial Carcinoma | Phase 2 | 2015-04-01 |
| Completed | ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate Rheumatoid Arthritis | Phase 2 | 2015-04-01 |
| Active Not Recruiting | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma Mantle Cell Lymphoma (MCL) | Phase 2 | 2015-03-02 |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL) | Phase 1 / Phase 2 | 2015-02-20 |
| Completed | An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myelom Multiple Myeloma (MM) | Phase 1 | 2015-02-01 |
| Completed | Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2015-01-12 |
| Active Not Recruiting | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma Non Hodgkin Lymphoma | Phase 1 / Phase 2 | 2014-12-29 |
| Completed | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia | Phase 1 | 2014-12-22 |
| Completed | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies Non-Hodgkins Lymphoma, Multiple Myeloma, B-All | Phase 1 / Phase 2 | 2014-12-20 |
| Completed | A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196 Hepatic Insufficiency | Phase 1 | 2014-10-21 |
| Completed | A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196 Healthy Participants | Phase 1 | 2014-09-21 |
| Active Not Recruiting | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia Waldenström Macroglobulinemia (WM) | Phase 2 | 2014-09-11 |
| Active Not Recruiting | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia | Phase 1 | 2014-08-18 |
| Completed | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse L Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL) | Phase 1 | 2014-08-07 |
| Completed | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of AC Healthy Participants | Phase 1 | 2014-03-15 |
| Active Not Recruiting | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome | Phase 1 / Phase 2 | 2014-01-30 |